In addition to chimeric antigen receptor T-cell (CAR-T) therapy, antibody–drug conjugates, and targeted therapies such as Bruton's tyrosine kinase inhibitors and PI3 kinase inhibitors, bispecific T-cell redirectors have shown promising activity in this setting. The next generation of bispecific T-cell redirectors for non-Hodgkin lymphoma target CD20 (ie, epcoritamab, mosunetuzumab, glofitamab, odronextamab, plamotamab) and have defined pharmacokinetic properties and longer half-lives, enabling intermittent dosing and potentially subcutaneous administration, fewer serious toxic effects, and encouraging overall (39–96%) and complete (19–77%) response rates.4 In The Lancet, Martin Hutchings and colleagues5 report the results of the phase 1 dose-escalation part of an ongoing trial of the CD3xCD20 bispecific T-cell redirector, epcoritamab, in patients with CD20+ relapsed or refractory B-cell non-Hodgkin lymphoma (NCT03625037). Four patients developed transient neurological complications, including grade 1 partial seizure, grade 1 agraphia, grade 3 hypersomnia, and grade 3 confusion; however, immune effector cell-associated neurotoxicity syndrome (ICANS) grading was not used, limiting cross-product or cross-trial comparisons (grade 1 partial seizure would be considered grade 3 ICANS).6 Fever was the only serious treatment-related adverse event occurring in more than 5% of participants and no patient had febrile neutropenia or discontinued therapy due to adverse events.